OVID Latest Press Releases

-- December 18, 2025 --

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) Globe Newswire 8:00 AM

-- December 2, 2025 --

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer Globe Newswire 7:00 AM

-- November 12, 2025 --

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results Globe Newswire 7:00 AM

-- October 3, 2025 --

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds Globe Newswire 7:05 AM

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile Globe Newswire 7:00 AM

-- August 13, 2025 --

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software